J. Mark Sloan

4.4k total citations
143 papers, 2.4k citations indexed

About

J. Mark Sloan is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, J. Mark Sloan has authored 143 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 38 papers in Hematology and 36 papers in Genetics. Recurrent topics in J. Mark Sloan's work include Amyloidosis: Diagnosis, Treatment, Outcomes (57 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (17 papers) and Chronic Myeloid Leukemia Treatments (15 papers). J. Mark Sloan is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (57 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (17 papers) and Chronic Myeloid Leukemia Treatments (15 papers). J. Mark Sloan collaborates with scholars based in United States, United Kingdom and Spain. J. Mark Sloan's co-authors include Shayna Sarosiek, Vaishali Sanchorawala, W. Glenn McCluggage, David C. Seldin, Mark Crowther, Anthony C Shelton, Karen Quillen, Dina Brauneis, Gheorghe Doros and John L. Berk and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

J. Mark Sloan

129 papers receiving 2.4k citations

Peers

Countries citing papers authored by J. Mark Sloan

Since Specialization

Citations

This map shows the geographic impact of J. Mark Sloan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Mark Sloan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Mark Sloan more than expected).

Fields of papers citing papers by J. Mark Sloan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Mark Sloan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Mark Sloan. The network helps show where J. Mark Sloan may publish in the future.

Co-authorship network of co-authors of J. Mark Sloan

This figure shows the co-authorship network connecting the top 25 collaborators of J. Mark Sloan. A scholar is included among the top collaborators of J. Mark Sloan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Mark Sloan. J. Mark Sloan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Implementation of a Duffy antigen screening test order with interpretation guide to help optimize resource allocation at an urban safety‐net hospital 2025 ·Transfusion ·(unknown), (unknown), J. Mark Sloan, (unknown), (unknown)	0
2	Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone ( BV ‐ CHEP ) for the treatment of aggressive adult T‐cell leukaemia/lymphoma 2025 ·British Journal of Haematology ·Christopher Dittus, Matthew Weinstock, Jeffrey A. Barnes, Jose Sandoval‐Sus, Natalie S. Grover, Anne Beaven, (unknown), Anthony C Shelton, Xianming Tan, (unknown), Areej El‐Jawahri, Shayna Sarosiek, J. Mark Sloan	1
3	The Association of Anticoagulation Intensity with Outcomes in Hospitalized COVID‐19 Patients 2024 ·Advances in Hematology ·Rena Zheng, (unknown), (unknown), (unknown), (unknown), (unknown), Michael A. Garcia, Robert T. Eberhardt, J. Mark Sloan, Janice Weinberg, Elizabeth S. Klings	1
4	Final Results of a Multicenter Pilot Study Evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Aggressive Adult T-Cell Leukemia/Lymphoma 2023 ·Blood ·Christopher Dittus, Matthew Weinstock, Jeffrey A. Barnes, Jose Sandoval‐Sus, Natalie S. Grover, Anne Beaven, Xianming Tan, Areej El‐Jawahri, Shayna Sarosiek, J. Mark Sloan	1
5	Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/ Refractory Light Chain Amyloidosis Previously Exposed to Daratumumab 2023 ·Blood ·Cara A. Rosenbaum, Michaela Liedtke, Paul J. Christos, Hye Min Kim, (unknown), (unknown), (unknown), Anthony C Shelton, Samantha M. Reilly, (unknown), J. Mark Sloan, Vaishali Sanchorawala, Anita D’Souza	1
6	Risk factors for Venous Thromboembolism and clinical outcomes in adults with sickle cell disease 2022 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Romy Lawrence, (unknown), Julia Newman, (unknown), (unknown), (unknown), Robyn T. Cohen, J. Mark Sloan, Mehdi Nouraie, Elizabeth S. Klings	5
7	Vaccine-Induced Immune Thrombotic Thrombocytopenia with Concurrent Arterial and Venous Thrombi Following Ad26.COV2.S Vaccination 2021 ·Journal of Stroke and Cerebrovascular Diseases ·Andreas Charidimou, (unknown), Anna M. Cervantes‐Arslanian, J. Mark Sloan, Hormuzdiyar H. Dasenbrock, Ali Daneshmand	8
8	SARS-CoV-2 Infection–Associated Hemophagocytic Lymphohistiocytosis 2020 ·American Journal of Clinical Pathology ·(unknown), (unknown), (unknown), (unknown), (unknown), Qing Zhao, Yachana Kataria, Shayna Sarosiek, Adam Lerner, J. Mark Sloan, Karen Quillen, Eric Burks	90
9	Acute promyelocytic leukaemia presenting as necrotising fasciitis of the perineum (Fournier gangrene) 2018 ·BMJ Case Reports ·(unknown), Felipe Batalini, Pedro V. Staziaki, (unknown), J. Mark Sloan	1
10	Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study 2017 ·Blood ·Vaishali Sanchorawala, Shayna Sarosiek, J. Mark Sloan, Dina Brauneis, (unknown), (unknown), (unknown), Salli Fennessey, Anthony C Shelton	13
11	Brachial Plexopathy Following High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation for AL Amyloidosis 2017 ·Blood ·Vina P. Nguyen, Dina Brauneis, J. Mark Sloan, Shayna Sarosiek, Karen Quillen, Anthony C Shelton, Vaishali Sanchorawala	0
12	Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis 2015 ·Haematologica ·Katherine M. Bever, Luke Masha, Fangui Sun, Lauren Stern, Andrea Havasi, John L. Berk, Vaishali Sanchorawala, David C. Seldin, J. Mark Sloan	22
13	Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial 2015 ·Biology of Blood and Marrow Transplantation ·Vaishali Sanchorawala, Dina Brauneis, Anthony C Shelton, Stephen Lo, Fangui Sun, J. Mark Sloan, Karen Quillen, David C. Seldin	49
14	Colitis complicating chronic granulomatous disease. A clinicopathological case report. 1996 ·Gut ·J. Mark Sloan, C. H. S. Cameron, Ramona Maxwell, D R McCluskey, J. S. A. Collins	25
15	Surface Features of Small‐Intestinal Mucosa in Childhood Diarrheal Disorders 1996 ·Journal of Pediatric Gastroenterology and Nutrition ·Patricia McClean, J.A. Dodge, (unknown), K. E. Carr, J. Mark Sloan	1
16	Development of a staging system for chemotherapy-induced stomatitis 1991 ·Cancer Nursing ·(unknown), (unknown), (unknown), Lesley F. Degner, (unknown), Harry Plummer, Norma J. Stewart, Norma E. Thurston, (unknown), J. Mark Sloan	25
17	Relationship between histology and gastric juice pH and nitrite in the stomach after operation for duodenal ulcer. 1984 ·Gut ·(unknown), J. Mark Sloan, (unknown), C. C. Patterson, T Kennedy	39
18	Changes in gastric mucosa after vagotomy and gastrojejunostomy for duodenal ulcer. 1983 ·BMJ ·(unknown), J. Mark Sloan, T Kennedy	19
19	Histology of the postoperative stomach before and after diversion of bile. 1983 ·BMJ ·(unknown), J. Mark Sloan, A F Spencer, T Kennedy	23
20	Changes in N-terminal glucagon-like immunoreactivity and insulin during short-term gluten challenge in childhood coeliac disease. 1981 ·Gut ·D. J. Carson, J. F. T. Glasgow, K. D. Buchanan, J. Mark Sloan	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact